Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Alzheimer’s: Can It Support Memory and Slow Cognitive Decline?
Transcript
- 0:00SPEAKER_02: Welcome to the Sarana Cell Podcast.
- 0:02SPEAKER_00: Glad to be here.
- 0:02SPEAKER_02: So I want you to imagine for a second that you are reaching for a word.
- 0:07SPEAKER_02: It is, you know, right there, hovering on the tip of your tongue.
- 0:10SPEAKER_02: But instead of finding it, you realize the entire mental filing cabinet where you kept that word is, well, simply gone.
- 0:18SPEAKER_00: Yeah, it's a terrifying thought.
- 0:19SPEAKER_02: It really is.
- 0:20SPEAKER_02: And tomorrow, it might be the route to the grocery store you've driven for 20 years.
- 0:24SPEAKER_02: Next month, it might be the name of a lifelong friend.
- 0:27SPEAKER_01: Right.
- 0:28SPEAKER_02: That is the creeping, devastating reality of Alzheimer's disease.
- 0:33SPEAKER_02: So today we are undertaking a deep dive into a stack of materials detailing stem cell therapy for Alzheimer's.
- 0:40SPEAKER_02: And we're going to have a specific focus on the approach being utilized by Sronosol, which is uh a doctor-led regenerative medicine center based in Kuala Lumpur, Malaysia.
- 0:49SPEAKER_00: Exactly.
- 0:50SPEAKER_02: Our mission today is basically to bypass all the medical jargon, scrutinize the science, and figure out exactly what modern regenerative medicine is actually doing to support brain health.
- 0:59SPEAKER_00: Aaron Powell Because, I mean, in a world that is just overflowing with exaggerated medical claims and, you know, internet miracle cures.
- 1:06SPEAKER_02: Well, there's so many of them out there.
- 1:08SPEAKER_00: Right, there really are.
- 1:09SPEAKER_00: So we have to approach this topic with intense rigor.
- 1:12SPEAKER_00: Alzheimer's fundamentally alters a person's memory, their behavior, and their independence.
- 1:18SPEAKER_00: And to be unequivocally clear, right at the top, there is no proven cure for Alzheimer's disease.
- 1:24SPEAKER_02: Right.
- 1:24SPEAKER_02: We really need to emphasize that.
- 1:26SPEAKER_00: Exactly.
- 1:27SPEAKER_00: The clinical materials we are examining today, they do not claim to offer one.
- 1:31SPEAKER_00: Instead, we are looking at a highly structured, science-led pivot.
- 1:35SPEAKER_00: Okay.
- 1:36SPEAKER_00: We are analyzing how specific, carefully monitored cellular therapies are being utilized as an adjunct-like, a supportive addition to standard neurological care.
- 1:46SPEAKER_00: We are looking at safe, scientifically grounded support, not, you know, a magic fix.
- 1:51SPEAKER_02: Okay, let's unpack this.
- 1:52SPEAKER_02: Yeah.
- 1:53SPEAKER_02: Because to really understand why a doctor would even consider using stem cells for a brain condition, we first have to understand what is actually going wrong inside the skull of someone suffering from Alzheimer's.
- 2:03SPEAKER_02: Right.
- 2:04SPEAKER_02: Reading through these reports, it becomes clear this isn't just um, you know, getting older or normal forgetfulness.
- 2:11SPEAKER_00: No, not at all.
- 2:12SPEAKER_02: There's a very specific type of physical damage occurring.
- 2:14SPEAKER_00: Yeah, the physical pathology of Alzheimer's is marked by the accumulation of rogue elements in the brain.
- 2:20SPEAKER_00: Specifically, we see a buildup of two types of toxic, sticky proteins.
- 2:26SPEAKER_02: And those are the amyloid and tau proteins, right?
- 2:28SPEAKER_00: Exactly.
- 2:28SPEAKER_00: Amyloid plaques, which sort of clump together between the neurons, and then tau tangles, which physically twist up inside the cells themselves.
- 2:36SPEAKER_00: Oh wow.
- 2:36SPEAKER_00: Now your brain is a highly evolved organ, so it detects this buildup as a literal threat.
- 2:42SPEAKER_00: The brain's localized immune system, its emergency responders, basically detects this protein garbage and switches on to clear it out.
- 2:50SPEAKER_02: Which sounds like a good thing initially.
- 2:52SPEAKER_00: It is.
- 2:52SPEAKER_00: But the problem is because the toxic proteins just keep forming, the immune system stays switched on permanently.
- 2:59SPEAKER_02: Right.
- 2:59SPEAKER_02: And the text describes that permanent alarm state as chronic neuroinflammation.
- 3:05SPEAKER_02: You know, visualizing this, an image kept coming to my mind to help make sense of all the cellular chaos.
- 3:10SPEAKER_00: Oh, what's that?
- 3:11SPEAKER_02: Think of the healthy brain like a bustling, perfectly organized city.
- 3:15SPEAKER_02: Everything is working fine, the roads are clear, the power grid is humming.
- 3:19SPEAKER_02: But then small, stubborn fires start breaking out in different neighborhoods.
- 3:24SPEAKER_00: And those fires are our sticky amyloid and tau proteins.
- 3:28SPEAKER_02: Exactly.
- 3:28SPEAKER_02: Naturally, the city's fire alarms go off and the emergency responders rush in.
- 3:32SPEAKER_00: And well, under normal circumstances, those responders put out the fire, clean up the debris, and go back to the station.
- 3:38SPEAKER_02: Right.
- 3:39SPEAKER_02: They rest.
- 3:40SPEAKER_02: But in this Alzheimer's city, the fire alarms get physically stuck in the on position.
- 3:44SPEAKER_02: They just never stop ringing.
- 3:46SPEAKER_02: Those emergency responders are now running around the clock, utterly exhausted, spraying high-pressure water everywhere in a total panic.
- 3:54SPEAKER_02: Because of all this chaos, the chronic stress and the flooding, the normal day-to-day city maintenance just completely stops.
- 4:01SPEAKER_00: Yeah, the infrastructure breaks down.
- 4:03SPEAKER_02: Exactly.
- 4:03SPEAKER_02: The garbage trucks stop running, the potholes aren't fixed, the power lines snap.
- 4:08SPEAKER_02: The complex networks that allow the city to actually function break down.
- 4:12SPEAKER_02: And when it comes to standard medicines for Alzheimer's, it seems a bit like giving the exhausted firefighters, I don't know, a megaphone or an energy drink.
- 4:22SPEAKER_00: Aaron Powell Right.
- 4:22SPEAKER_00: They might manage the smoke for a little while, but they aren't fixing the damaged buildings.
- 4:27SPEAKER_00: Trevor Burrus, Jr.
- 4:27SPEAKER_02: Or turning off the broken alarms.
- 4:28SPEAKER_00: Trevor Burrus And that is the exact limitation of standard pharmacological interventions.
- 4:33SPEAKER_00: I mean, they are absolutely vital for managing symptoms, but they do not rebuild damaged tissue or fundamentally alter the hostile inflammatory environment of the brain.
- 4:42SPEAKER_00: They just cannot repair the roads.
- 4:44SPEAKER_00: This is the precise gap in care where the concept of scem cell therapy enters our clinical materials.
- 4:51SPEAKER_00: But we really need to dispel a very common myth right now.
- 4:53SPEAKER_01: Okay, let's hear it.
- 4:54SPEAKER_00: The goal is not to take a stem cell, inject it into the brain, and have it instantly magically transform into a brand new, perfectly functioning memory cell to replace a dead one.
- 5:04SPEAKER_02: I think that is exactly what most people, myself included, assume when they hear the phrase stem cell therapy.
- 5:11SPEAKER_02: You just assume it's a one-for-one parts replacement.
- 5:14SPEAKER_00: It is a totally logical assumption, but biology is much more nuanced than that.
- 5:19SPEAKER_00: Instead of replacement parts, we need to think of these specific stem cells as highly specialized support units or like biological managers.
- 5:27SPEAKER_02: Biological managers, I like that.
- 5:28SPEAKER_00: Yeah.
- 5:29SPEAKER_00: When they're introduced into the body, their primary function is repair, protection, and communication.
- 5:34SPEAKER_00: They secrete powerful chemical signals designed to calm that chronic inflammation.
- 5:39SPEAKER_00: They essentially walk into your chaotic city, turn off the broken fire alarms, and tell the exhausted immune responders to stand down and get some rest by drastically cooling off that local inflammatory environment.
- 5:52SPEAKER_00: They give the surviving struggling neurons a chance to breathe, to actually function, and to repair their own networks.
- 5:58SPEAKER_02: Well, because the brain desperately needs this highly specialized management, our sources lead us right into where these support units come from and you know how they are prepared.
- 6:07SPEAKER_02: Which brings us to the operational model of Cyrona cell over in Kuala Lumpur.
- 6:12SPEAKER_02: They are drawing patients from across the globe, from Australia, the Middle East, across Asia, specifically for this medically supervised cell therapy.
- 6:22SPEAKER_02: And the name of the clinic itself jumped out at me.
- 6:24SPEAKER_02: Thirona was a Celtic goddess of health, healing, and protection.
- 6:29SPEAKER_02: Feels very intentional prioritizing the idea of a protective sanctuary over flashy quick fix promises.
- 6:36SPEAKER_00: It does.
- 6:36SPEAKER_00: And the clinical documentation backs up that ethos with incredibly strict laboratory and sourcing standards.
- 6:42SPEAKER_00: Let's actually look at the biological material they utilize.
- 6:45SPEAKER_01: Okay.
- 6:45SPEAKER_00: Cyronacell exclusively uses what are known as early passage WJ MSEs.
- 6:50SPEAKER_02: All right, let's break that acronym down.
- 6:52SPEAKER_02: Sure.
- 6:52SPEAKER_00: So MSC stands for mesenchymal stem cell.
- 6:55SPEAKER_00: These are adult type stem cells known for their signaling and healing properties.
- 6:59SPEAKER_00: And the WJ stands for Wharton's Jelly.
- 7:01SPEAKER_02: Wharton's Jelly?
- 7:02SPEAKER_00: Yeah.
- 7:02SPEAKER_00: This is the gelatinous tissue found inside a human umbilical cord.
- 7:05SPEAKER_02: Wait, so they are sourcing these cells from umbilical cords, like right after a baby is born.
- 7:09SPEAKER_00: Correct.
- 7:10SPEAKER_00: They are ethically sourced from healthy, full-term deliveries with complete voluntary donor consent from the mother.
- 7:17SPEAKER_00: The umbilical cord, which you know is normally just discarded as medical waste, is incredibly rich in these vibrant day zero stem cells.
- 7:24SPEAKER_00: Amazing.
- 7:24SPEAKER_00: Because they are from a newborn cord, they haven't been subjected to decades of environmental toxins, stress, or just regular aging.
- 7:32SPEAKER_00: Furthermore, the laboratory processes these cells under BSL2 and CGMP standards.
- 7:38SPEAKER_02: Okay, wait, let's translate that alphabet soup for the listener.
- 7:41SPEAKER_02: Yeah.
- 7:41SPEAKER_02: What do BSL2 and CGMP actually mean for the person walking into the clinic?
- 7:46SPEAKER_00: Fair question.
- 7:47SPEAKER_00: BSL2 stands for Biosafety Level 2, and CGMP stands for current good manufacturing practice.
- 7:54SPEAKER_00: In plain terms, it means the laboratory operates with the same ultra-strict, sterile, highly regulated conditions used to manufacture pharmaceutical drugs.
- 8:02SPEAKER_00: Ah, got it.
- 8:03SPEAKER_00: It ensures that every single back of cells undergoes rigorous testing for identity, purity, sterility, and viability before it ever reaches a patient.
- 8:11SPEAKER_00: They aren't just mixing things in a back room somewhere.
- 8:13SPEAKER_02: Right, it's highly regulated.
- 8:14SPEAKER_00: Exactly.
- 8:15SPEAKER_00: And just as importantly, the clinical materials explicitly state what they refuse to use.
- 8:19SPEAKER_00: Which is absolutely no embryonic stem cells and no experimental pluripotent stem cells.
- 8:26SPEAKER_02: Aaron Powell Why the hard line against pluripotent cells, though?
- 8:29SPEAKER_02: Because I've seen that word thrown around in biotech articles as the sort of holy grail.
- 8:34SPEAKER_02: Because they can turn into any cell in the body.
- 8:36SPEAKER_00: They can, which makes them fascinating for laboratory research, but highly unpredictable in a human patient.
- 8:41SPEAKER_00: Pluripotent cells have a known risk of forming tumors because their growth can be really difficult to control.
- 8:46SPEAKER_02: Oh wow.
- 8:47SPEAKER_02: I had no idea.
- 8:48SPEAKER_00: Yeah.
- 8:49SPEAKER_00: Mesenchymal stem cells, on the other hand, do not carry that tumor risk.
- 8:53SPEAKER_00: They are stable, safe, and entirely focused on managing inflammation and tissue repair, which is why a doctor-led facility prioritizes them.
- 9:01SPEAKER_02: Okay, but I have to push back here.
- 9:03SPEAKER_02: I have to play the skeptic for a second because this is the very first question that popped into my head when reading about Wharton's jelly.
- 9:09SPEAKER_00: Lay it on me.
- 9:10SPEAKER_02: Wait a minute.
- 9:11SPEAKER_02: If they aren't using the patient's own biological material, how does an umbilical cord cell from a completely different person, a literal newborn baby, know what to do inside an older adult's brain?
- 9:23SPEAKER_00: It's a great question.
- 9:24SPEAKER_02: Won't the older adult's body just reject it as foreign tissue?
- 9:28SPEAKER_00: What's fascinating here is the unique biological privilege of misenchymal stem cells.
- 9:33SPEAKER_00: They are fundamentally adaptable and immune evasive.
- 9:37SPEAKER_02: Immune evasive.
- 9:38SPEAKER_00: Yeah.
- 9:38SPEAKER_00: They do not display the specific protein markers on their surface that usually trigger our immune system to attack foreign invaders.
- 9:46SPEAKER_00: Therefore, they don't need to perfectly match the patient's own tissue to be safely administered and effective.
- 9:52SPEAKER_00: They operate like universal biological diplomats.
- 9:56SPEAKER_02: So they can just slip into the body without setting off the security alarms.
- 9:59SPEAKER_00: Exactly.
- 10:00SPEAKER_00: And once they are in, they respond to the distress signals being sent out by the patient's damaged tissue.
- 10:05SPEAKER_00: The inflammatory environment of the older adult's brain acts like a homing beacon.
- 10:10SPEAKER_02: That is incredible.
- 10:12SPEAKER_00: It is.
- 10:12SPEAKER_00: Guided by the rigorous standards of the medical team, which, by the way, the clinic notes include specialists in internal medicine, neurology, and rehabilitation, these universal cells begin acting as powerful signaling factories.
- 10:26SPEAKER_00: They pump out factors that promote blood vessel growth and actively calm the immune response.
- 10:31SPEAKER_02: Which brings us to the actual delivery of these biological diplomats.
- 10:34SPEAKER_00: Right.
- 10:35SPEAKER_02: How do they actually get to the battlefield?
- 10:37SPEAKER_02: Right.
- 10:37SPEAKER_02: The text notes this is achieved without any invasive brain surgery.
- 10:42SPEAKER_02: Typically, it is just an IV infusion directly into the bloodstream.
- 10:46SPEAKER_02: And the clinical goals are clear, right?
- 10:48SPEAKER_02: Reduce neuroinflammation, support the blood vessels so more oxygen reaches the brain, and protect the surviving neurons.
- 10:54SPEAKER_02: But here's where it gets really interesting and where my skepticism flared up again.
- 10:58SPEAKER_02: If this is just an IV drip into my arm, how on earth is it fixing a buildup of toxic proteins inside my skull?
- 11:05SPEAKER_00: Uh huh.
- 11:06SPEAKER_02: Doesn't the human body have a blood brain barrier specifically designed as an evolutionary fortress to block things in the bloodstream from getting into the brain tissue?
- 11:14SPEAKER_00: If we connect this to the bigger picture of human anatomy, your skepticism is entirely justified.
- 11:19SPEAKER_00: The blood brain barrier is indeed a formidable fortress.
- 11:23SPEAKER_00: It's a highly selective filter protecting the brain from pathogens in the blood.
- 11:27SPEAKER_00: Right.
- 11:28SPEAKER_00: But the science, detailed in our stack of research, shows that these stem cells don't necessarily need to physically breach that wall in massive, overwhelming numbers to save the city.
- 11:39SPEAKER_01: Wait, how is that possible?
- 11:40SPEAKER_01: If they don't cross the wall, how do they help the brain?
- 11:43SPEAKER_00: Because the brain does not exist in a vacuum, right?
- 11:46SPEAKER_00: It is connected to the systemic environment of your entire body.
- 11:49SPEAKER_00: When these stem cells circulate through the bloodstream via the IFV, they act systemically.
- 11:54SPEAKER_01: Okay.
- 11:55SPEAKER_00: They improve overall vascular health and blood flow, but more importantly, they release those powerful chemical signals, proteins, and growth factors we discussed earlier.
- 12:04SPEAKER_00: And many of these microscopic signaling molecules can slip through the blood-brain barrier.
- 12:09SPEAKER_01: Oh, I see.
- 12:10SPEAKER_00: Furthermore, the stem cells interact with the systemic immune cells circulating in your body, calming them down.
- 12:16SPEAKER_00: By cooling the inflammatory waters of the entire body, you drastically lower the inflammatory tide affecting the brain.
- 12:23SPEAKER_00: They change the overarching environment rather than trying to batter down the fortress gates.
- 12:29SPEAKER_02: That completely fliffs the perspective.
- 12:31SPEAKER_02: They are treating the whole ecosystem to heal the brain.
- 12:34SPEAKER_00: Exactly.
- 12:34SPEAKER_02: And the sources actually back up this systemic approach with two incredibly compelling clinical studies.
- 12:41SPEAKER_02: First, there's data from Kunming Medical University in China.
- 12:44SPEAKER_02: They conducted a study on older adults suffering from vascular dementia.
- 12:49SPEAKER_02: Now, vascular dementia isn't Alzheimer's, it's caused by reduced blood flow to the brain, but it is a severe condition causing profound memory and cognitive decline.
- 12:58SPEAKER_02: The researchers used human umbilical cord-derived MSCs delivered via standard IV infusions, just like the protocol we were discussing.
- 13:06SPEAKER_00: Yeah, and the clinical outcomes of that study are vital for establishing a baseline of trust.
- 13:10SPEAKER_00: The researchers rigorously tracked the patient's memory function and their ability to perform daily activities.
- 13:15SPEAKER_02: And what did they find?
- 13:16SPEAKER_00: They reported measurable short-term improvements in cognitive function.
- 13:20SPEAKER_00: But, you know, beyond the cognitive bump, the most critical takeaway was safety.
- 13:25SPEAKER_00: They demonstrated that this systemic IV approach was incredibly safe, well tolerated, and highly feasible for elderly patients with serious neurodegenerative disorders.
- 13:35SPEAKER_02: So it basically proves the delivery mechanism is sound.
- 13:38SPEAKER_00: Right.
- 13:39SPEAKER_02: But the second study from Sun King Kwan University School of Medicine in South Korea takes it a step further into the specific pathology of Alzheimer's.
- 13:48SPEAKER_02: And this one is genuinely mind-blowing.
- 13:51SPEAKER_00: It really is.
- 13:52SPEAKER_02: The researchers wanted to see how these exact mesenchymal stem cells behave when they are dropped directly into an Alzheimer's-like environment.
- 13:59SPEAKER_00: This is where we see the adaptive intelligence of these cells.
- 14:02SPEAKER_02: Right.
- 14:02SPEAKER_02: The study found that priming the stem cells, essentially exposing them to the disease-like setting in a laboratory before using them, actually hypercharge their abilities.
- 14:11SPEAKER_02: When the cells encountered that specific environment, they upregulated their therapeutic response.
- 14:17SPEAKER_02: Yeah.
- 14:17SPEAKER_02: They actively enhanced the helpful signals they sent out to fight against those specific toxic amyloid and tau proteins we talked about earlier.
- 14:25SPEAKER_00: And that concept of cellular priming is a critical piece of the regenerative puzzle.
- 14:30SPEAKER_00: It proves that these cells are not static, you know, they are highly reactive machines.
- 14:36SPEAKER_00: When they encounter the specific chemical stress of an Alzheimer's environment, they adapt their output to meet the threat.
- 14:42SPEAKER_01: That's wild.
- 14:43SPEAKER_00: It reinforces exactly why a dynamic multi-target therapy like this is being utilized for a disease where inflammation, protein buildup, and cellular stress are all crashing together at once.
- 14:54SPEAKER_02: Well, given all this compelling science, the adaptable nature of the cells, and the proven safety of the IV delivery, the immediate next question for anyone listening who is dealing with this diagnosis is who is this actually for?
- 15:05SPEAKER_00: Yeah.
- 15:05SPEAKER_02: What does the process look like for a real human being flying into Kuala Lumpur?
- 15:10SPEAKER_00: We have to ground ourselves again and reiterate the hardest truth in this entire discussion.
- 15:15SPEAKER_00: The materials from Cyrona Cell are explicit about managing expectations up front.
- 15:19SPEAKER_00: The goal of this therapy is not a miraculous reversal of advanced dementia.
- 15:24SPEAKER_02: They aren't going to restore memories that have already been completely destroyed.
- 15:28SPEAKER_00: Exactly.
- 15:28SPEAKER_00: The clinical goal is slowing the trajectory of cognitive decline.
- 15:32SPEAKER_00: It is about buying time and maintaining day-to-day independence and quality of life for as long as biologically possible.
- 15:39SPEAKER_00: Right.
- 15:39SPEAKER_00: Therefore, the ideal candidate is typically someone in the early to moderate stages of the disease where there is still significant brain function left to protect and support.
- 15:49SPEAKER_00: No.
- 15:49SPEAKER_00: Candidacy is definitely not guaranteed.
- 15:52SPEAKER_00: It is determined through a strict, personalized evaluation.
- 15:55SPEAKER_00: The medical team meticulously reviews recent MRI or PE scans to understand the physical topography of the brain, alongside a deep dive into the patient's cognitive history, memory tests, and overall physical fitness to endure travel and treatment.
- 16:10SPEAKER_02: Let's actually walk through what the patient pathway looks like because the clinic has it structured into four very deliberate steps.
- 16:16SPEAKER_00: Okay.
- 16:16SPEAKER_02: Step one is the medical evaluation.
- 16:18SPEAKER_02: This happens before you ever get near a treatment room.
- 16:21SPEAKER_02: It's a comprehensive review of your reports to set those realistic aims.
- 16:26SPEAKER_02: Then, step two is stem cell preparation.
- 16:30SPEAKER_02: This happens totally out of sight in the laboratory, where the scientists are utilizing those strict CGMP standards to test the batch for absolute purity and strength.
- 16:40SPEAKER_00: Right, and that preparation step ensures that the biological material is perfectly optimized and safe before it is ever cleared for clinical use.
- 16:48SPEAKER_02: Then we move to step three, which is the administration.
- 16:50SPEAKER_02: And based on everything we've discussed, it's remarkably anticlimactic in a good way.
- 16:54SPEAKER_02: It's a relaxing, minimally invasive IV drip.
- 16:58SPEAKER_02: No general anesthesia, no invasive surgery.
- 17:01SPEAKER_02: Finally, step four is monitoring and follow-up.
- 17:04SPEAKER_02: The medical team doesn't just, you know, wave goodbye, they actively track changes in the patient's memory, mood, sleep patterns, and daily function over the weeks and months after they return home.
- 17:14SPEAKER_00: That follow-up is crucial.
- 17:16SPEAKER_02: Yeah, but nested within this pathway, the materials introduce one more layer to the therapy.
- 17:21SPEAKER_02: It's an added value service called exosomes.
- 17:23SPEAKER_00: Ah, yes.
- 17:24SPEAKER_00: Exosomes represent the absolute cutting edge of regenerative science right now.
- 17:30SPEAKER_00: They are microscopic extracellular vesicles, essentially tiny messenger packets that are naturally secreted by the stem cells.
- 17:38SPEAKER_02: Okay, let me try to wrap my head around this with another analogy.
- 17:41SPEAKER_02: Go for it.
- 17:42SPEAKER_02: If we go back to our city and the stem cells are the foreman on a construction site assessing the damage and organizing the repair strategy, then the exosomes are the millions of text messages, emails, and blueprints they send out from their phones to get all the local workers moving.
- 17:58SPEAKER_00: That's a great way to put it.
- 17:59SPEAKER_02: They carry the vital instructions that tell the local immune cells to calm the inflammation and initiate repair.
- 18:04SPEAKER_00: That is exactly how they function, because they are just tiny packets of information and growth factors and not whole cells, they are incredibly small.
- 18:12SPEAKER_00: This allows them to penetrate deep into tissues and cross biological barriers with remarkable ease.
- 18:19SPEAKER_00: By combining targeted exosome therapy with the foundational stem cell therapy, the clinic aims to basically saturate the body with these healing instructions, strengthening the overall supportive plan.
- 18:31SPEAKER_00: But analyzing all of this medical capability, well, this raises an important question.
- 18:35SPEAKER_00: Which is the ethics of hope.
- 18:38SPEAKER_00: When families are navigating the darkness of an Alzheimer's diagnosis, they are often desperate, they are vulnerable, and frankly, they will empty their bank accounts to try anything.
- 18:48SPEAKER_01: Yeah, it's heartbreaking.
- 18:50SPEAKER_00: What stands out most prominently in the operational materials of Cirona Cell is their absolute commitment to telling a patient no.
- 18:56SPEAKER_01: Really?
- 18:57SPEAKER_00: Yes.
- 18:57SPEAKER_00: If the medical team evaluates a file and believes a patient will not meaningfully benefit from the program, perhaps because the disease has progressed too far, or their overall health makes the journey risky, they will honestly and directly tell them no.
- 19:11SPEAKER_02: So they are choosing to prioritize long-term medical trust over, you know, just selling a one-time procedure to a desperate family.
- 19:19SPEAKER_00: Precisely.
- 19:20SPEAKER_00: Furthermore, they insist on combining cell therapy with a patient's existing standard neurological pair.
- 19:26SPEAKER_00: They don't tell you to throw away your current medications.
- 19:29SPEAKER_00: It is strictly an adjunct.
- 19:31SPEAKER_00: Right.
- 19:31SPEAKER_00: That is the hallmark of the most responsible ethical medical approach you can take in the regenerative field today.
- 19:37SPEAKER_00: It deeply respects both the physical safety of the patient and the emotional expectations of the family.
- 19:43SPEAKER_02: So, what does this all mean for you listening right now?
- 19:45SPEAKER_02: We've covered some incredibly dense, fascinating ground today.
- 19:49SPEAKER_02: We've seen that stem cell therapy for Alzheimer's is not an overnight miracle or a memory replacement machine.
- 19:55SPEAKER_00: No, it's not.
- 19:56SPEAKER_02: Rather, it is a highly sophisticated science-backed support system.
- 20:00SPEAKER_02: It utilizes biological diplomats to systemically calm the immune system, acting like an emergency relief crew for a brain under chronic fiery stress.
- 20:08SPEAKER_02: And facilities like Cironacell in Malaysia represent a very structured, doctor-led approach to bringing this science out of the lab and into actual patient care.
- 20:17SPEAKER_02: They prioritize safety, the ethical sourcing of umbilical cord cells, strict laboratory standards, and most importantly, preserving the ongoing quality of life for the patient.
- 20:28SPEAKER_00: Ultimately, the objective is to optimize the body's internal environment, you know, giving the brain the best possible biological runway to maintain its function, its networks, and its memories for as long as possible.
- 20:40SPEAKER_02: If this deep dive resonated with you, or if you were currently navigating this difficult journey alongside a loved one, the materials suggest a very low pressure next step.
- 20:49SPEAKER_02: You can start with a simple calm review of your medical reports with the Serona cell team to see if this adjunct approach actually makes sense for your specific situation.
- 20:57SPEAKER_00: It's always worth asking the question.
- 20:59SPEAKER_02: But before we sign off, I want to leave you with a final thought to mull over.
- 21:02SPEAKER_00: When we look at the core mechanism here, how umbilical cord cells, the exact same biological units that help construct a human life from scratch at the very beginning, can be harnessed decades later to protect the stressed, aging brain.
- 21:16SPEAKER_00: Yeah.
- 21:16SPEAKER_00: It forces us to ask a profound question.
- 21:18SPEAKER_00: Yeah.
- 21:19SPEAKER_00: What other hidden regenerative languages is our own biology speaking that modern medicine is only just now beginning to translate?
- 21:26SPEAKER_02: A city with its firearms finally turned off, learning how to rebuild itself all over again.
- 21:31SPEAKER_00: Thanks for joining us for this deep dive.
- 21:32SPEAKER_00: Take care.